Home Newsletters Hematopoiesis News NPM1-Mutation-Based Measurable Residual Disease Assessment after Completion of Two Courses of Post-remission...

NPM1-Mutation-Based Measurable Residual Disease Assessment after Completion of Two Courses of Post-remission Therapy Is a Valuable Clinical Predictor of the Prognosis of Acute Myeloid Leukemia

By
Justin.choi
-
0
Scientists investigated the optimal timing and cutoff value to ascertain the value of NPM1 mutation in measurable residual disease assessment.
[International Journal of Hematology]

Sorry, but the selected Zotpress account can't be found.

Abstract

RELATED ARTICLES

Exit mobile version